Head to Head Contrast: NeuroOne Medical Technologies (NASDAQ:NMTC) and Pulmonx (NASDAQ:LUNG)

Pulmonx (NASDAQ:LUNG) and NeuroOne Medical Technologies (NASDAQ:NMTC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Institutional and Insider Ownership

91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. 5.7% of Pulmonx shares are owned by company insiders. Comparatively, 7.5% of NeuroOne Medical Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Risk and Volatility

Pulmonx has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, NeuroOne Medical Technologies has a beta of 0.73, meaning that its stock price is 27% less volatile than the S&P 500.

Profitability

This table compares Pulmonx and NeuroOne Medical Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pulmonx	-75.56%	-50.79%	-33.06%
NeuroOne Medical Technologies	-308.51%	-276.12%	-199.83%

Analyst Recommendations

This is a summary of recent ratings and target prices for Pulmonx and NeuroOne Medical Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulmonx	0	1	5	0	2.83
NeuroOne Medical Technologies	0	0	0	0	N/A

Pulmonx currently has a consensus target price of $14.83, indicating a potential upside of 122.39%. Given Pulmonx’s higher probable upside, equities analysts clearly believe Pulmonx is more favorable than NeuroOne Medical Technologies.

Valuation & Earnings

This table compares Pulmonx and NeuroOne Medical Technologies”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulmonx	$68.68 million	3.80	-$60.84 million	($1.50)	-4.45
NeuroOne Medical Technologies	$1.95 million	14.54	-$11.86 million	($0.48)	-1.92

NeuroOne Medical Technologies has lower revenue, but higher earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than NeuroOne Medical Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Pulmonx beats NeuroOne Medical Technologies on 7 of the 13 factors compared between the two stocks.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders. It also fucuses on applications for other areas, such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota.